Skip to main content

Table 2 Clinical characteristics associated with PPFE in all study patients with RA-ILD

From: Pleuroparenchymal fibroelastosis in rheumatoid arthritis-associated interstitial lung disease

Variables

Unadjusted analysis

Multivariable analysis

HR

95% CI

p-value

HR

95% CI

p-value

Age

1.029

0.988–1.071

0.165

   

Men

0.942

0.446–1.989

0.876

   

Ever-smokers

0.751

0.346–1.634

0.471

   

BMI

0.761

0.664–0.872

 < 0.001

0.771

0.668–0.889

 < 0.001

ESR

1.003

0.991–1.015

0.616

   

CRP

1.026

1.000–1.053

0.049

1.024

0.996–1.053

0.089

FVC

0.975

0.956–0.995

0.016

0.979

0.959–1.000

0.047

DLco

0.988

0.969–1.007

0.204

   

TLC

0.984

0.949–1.021

0.392

   

RV

1.009

0.981–1.038

0.547

   

UIP-like pattern on HRCT

3.056

0.911–10.246

0.070

2.615

0.756–9.038

0.129

Corticosteroid ± IM

1.285

0.607–2.717

0.512

   
  1. PPFE pleuroparenchymal fibroelastosis, RA rheumatoid arthritis, ILD interstitial lung disease, HR hazard ratio, CI confidence interval, BMI body mass index, RF rheumatoid factor, anti-CCP anti-cyclic citrullinated peptide, ESR erythrocyte sedimentation rate, CRP C-reactive protein, FVC forced vital capacity, DLco diffusing capacity for carbon monoxide, TLC total lung capacity, RV residual volume, UIP usual interstitial pneumonia, HRCT high-resolution chest tomography, IM immunosuppressant
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us